 |
Bachem is the world's sole peptide "full service provider", comprising
- 6 production sites with more than 15 buildings in the U.S. and in Europe
- Full cGMP manufacturing and research level production (both in the U.S.
and Europe)
- Capacity ranges from milligram amounts for preclinical work up to hundreds
of kilograms of active pharmaceutical ingredients (APIs) and tons of key intermediates.
- Manufacturing of peptidic and non-peptidic cytotoxic and cytostatic compounds.
- Production and release of finished dosage forms.
Our cGMP production sites in Bubendorf
(Switzerland), Vionnaz
(Switzerland) and Torrance
(USA) are inspected and approved by the FDA and local authorities. Production
and release of finished dosage forms under the responsibility of Bachem is conducted
in Weil
am Rhein (Germany).
Bachem's manufacturing capabilities are designed to meet actual and future customer needs in respect of
- Synthesis strategy (i.e. solid phase peptide synthesis, solution phase peptide synthesis)
- Protection groups (i.e. Boc-, Fmoc - processes)
- Purification strategy (i.e. preparative HPLC, conventional chromatography, ion exchange, gel chromatography, counter-current distribution)
- Flexibility and upscaling (i.e. reactors up to 8000 liters)
- Special customer request (i.e. dedicated production lines)
- Special equipment (i.e. enzymatic unit, electrolysis unit)
For finished dosage forms intended for clinical trials or commercial supply, Bachem
offers for its Active Pharmaceutical Ingredients (APIs)
- Formulation development
- Compatibility studies
- Sterile filling in cooperation with partners
- Release
- Stability studies
| |
